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Molecular profiling reveals primary mesothelioma cell
lines recapitulate human disease
T Chernova1,4, XM Sun1,4, IR Powley1, S Galavotti1, S Grosso1, FA Murphy1, GJ Miles1, L Cresswell3, AV Antonov1, J Bennett2, A Nakas2,
D Dinsdale1, K Cain1, M Bushell*,1, AE Willis*,1 and M MacFarlane*,1
Malignant mesothelioma (MM) is an aggressive, fatal tumor strongly associated with asbestos exposure. There is an urgent need to
improve MM patient outcomes and this requires functionally validated pre-clinical models. Mesothelioma-derived cell lines provide
an essential and relatively robust tool and remain among the most widely used systems for candidate drug evaluation. Although a
number of cell lines are commercially available, a detailed comparison of these commercial lines with freshly derived primary
tumor cells to validate their suitability as pre-clinical models is lacking. To address this, patient-derived primary mesothelioma cell
lines were established and characterized using complementary multidisciplinary approaches and bioinformatic analysis. Clinical
markers of mesothelioma, transcriptional and metabolic profiles, as well as the status of p53 and the tumor suppressor genes
CDKN2A and NF2, were examined in primary cell lines and in two widely used commercial lines. Expression of MM-associated
markers, as well as the status of CDKN2A, NF2, the ‘gatekeeper’ in MM development, and their products demonstrated that primary
cell lines are more representative of the tumor close to its native state and show a degree of molecular diversity, thus capturing the
disease heterogeneity in a patient cohort. Molecular profiling revealed a significantly different transcriptome and marked metabolic
shift towards a greater glycolytic phenotype in commercial compared with primary cell lines. Our results highlight that multiple,
appropriately characterised, patient-derived tumor cell lines are required to enable concurrent evaluation of molecular profiles
versus drug response. Furthermore, application of this approach to other difficult-to-treat tumors would generate improved
cellular models for pre-clinical evaluation of novel targeted therapies.
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Malignant mesothelioma (MM) is an aggressive, fatal tumor
strongly associated with asbestos exposure. MM is
responsible for ~ 3000 deaths per year in the United States
and 5000 deaths inWestern Europe.1 However, mortality rates
are expected to increase by 5–10% year on year in most
industrialized countries until about 2020,2 with the worldwide
incidence predicted to plateau around 2030. In recent years
the demography of MM has changed; the age of MM patients
has decreased and there is an increased incidence in females,
likely reflecting exposure from non-occupational sources.3
The major histologic subtypes of MM, epithelioid, sarcomatoid
and biphasic are all associated with poor patient survival, with
sarcomatoid MM exhibiting the worst prognosis.4 The median
overall survival for MM following frontline chemotherapy with
pemetrexed and cisplatin is ~ 12 months.5 The disease occurs
after a long (up to 40 years) latency period and the delay
between asbestos exposure and MM onset suggests that
multiple factors are involved in asbestos-induced tumorigen-
esis. Moreover, the non-specific early symptoms combined
with the older age of MM patients and the absence of reliable
biomarkers hinders early diagnosis.
There is an urgent need to improve MM patient outcomes
and this requires both appropriate pre-clinical models and new
therapeutic strategies. Mesothelioma-derived cell lines are
essential for the development of in vitro model systems,
thereby enabling mechanistic studies of tumor pathogenesis,
as well as the identification of new biomarkers and novel
therapeutic targets. A number of commercially available cell
lines have been widely used for translational in vitro studies.6
In addition, to date, several primary MM cell lines have been
described, although their degree of characterization
varies.7–12 It is generally accepted that these primary cell
lines are more physiologically relevant as in vitro models,
although the generation of such lines is both challenging and
labor intensive.
To evaluate in vitro models, a detailed comparison of long-
established commercially available MM cell lines with freshly
derived primary cell lines is essential. This is particularly
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important as MM is associated with chromosomal loss,
deletions in CDKN2A, CDKN2B, and NF213–15 genes and
mutations in BAP1 and CUL1.16 Thus, genomic instability
limits the long-term usefulness of commercially available MM
cell lines. To address this, and to develop more relevant
pre-clinical models of MM, we established and characterised
eight primary mesothelioma cell lines and employed a number
of complementary multidisciplinary approaches to examine
differences between these cell lines and two widely used
commercial cell lines. Our data demonstrate that there is a
significant difference between commercial and primary cell
lines at the molecular level, including the transcriptome,
expression of mesothelial markers and proteins associated
with MM pathogenesis including p53, metabolic profile, status
of the tumor suppressor genes CDKN2A and NF2 and their
products. Importantly, the commercial cell lines lack many key
molecular features known to be associated with MM, whereas
the eight primary cell lines more accurately recapitulate
human disease, thus providing a superior model for
pre-clinical evaluation of novel targeted therapies.
Results
Clinical specimens and establishment of primary
cultures. MM is one of the most difficult cancers in terms
of early diagnosis; as a result, tissue specimens representing
early stages of MM are not generally available. Surgically
resected tumor tissues were obtained from patients with
advanced epithelioid (six cases) or biphasic (two cases) MM
(Table 1), as surgery is not considered beneficial for patients
with sarcomatoid MM. Occupational exposure to asbestos
had been identified in five cases, whereas three patients had
no known history of exposure. Primary mesothelial cultures
were established by passaging the cells isolated from
resected tissue and were characterized at low (o10) and
high (30–50) passages.
Morphological appearance of primary mesothelioma cell
lines. Primary MM cell lines, including MESO-3T, MESO-7T,
MESO-8T, MESO-9T, MESO-12T, MESO-14T, MESO-17T
and MESO-27T, established in culture as an attached
monolayer (Figure 1a and b). Adherent cells exhibited
characteristic mesothelioid 'cobble-stone' morphology and
were occasionally multi-nucleated or vacuolated. The cell
lines were, to a certain extent, morphologically distinct and
doubling times varied from 31.6 to 141.6 h (Supplementary
Table 1). Long, thin, often branching microvilli on the cell
surface, a characteristic feature of mesothelial cells, were
observed in all primary cultures (Figure 1b and c). Primary
tumor cells in culture formed tight intercellular junctions
(Supplementary Figure S1), which are typically present
in mesothelial cell cultures.17 Primary MM cell lines
MESO-3T, MESO-7T, MESO-8T, MESO-12T, MESO-14T
and MESO-27T exhibited the ability to grow to high passage
(430), whereas MESO-9T and MESO-17T could only be
cultured for up to 15 passages before displaying signs of
senescence.
Expression of markers and proteins implicated in MM
pathogenesis differs between primary and commercial
cell lines. A panel of diagnostic markers and proteins
associated with MM development was examined in both
primary and commercial cell lines. Consistent with immuno-
chemistry results in the clinic (70–80% of mesotheliomas
have positive staining for pan-Cytokeratin18–20), western blot
analysis showed that five out of eight primary cell lines were
strongly positive for pan-Cytokeratin (Figure 2a). The
commercial cell line NCI-H2052 expressed pan-Cytokeratin,
whereas MSTO-211H cells were negative (Figure 2a).
Among the diagnostic markers of MM, Calretinin and
Podoplanin have the maximal sensitivity and selectivity.18–20
Calretinin was detected by western blot analysis in normal
mesothelial cells, with high levels evident in MESO-7T and
MESO-8T. The level of expression in the remaining primary
cell lines was significantly lower and appeared similar to that
detected in the commercial lines (Figure 2a). Confocal
microscopy of immunofluorescently stained cells showed
positive staining for Calretinin in all patient-derived cell lines,
with the highest level detected in MESO-7T and MESO-8T
(Figure 2b). Sequencing of the 46 Cancer Gene Panel
(including the tumor suppressor gene TP53 and
proto-oncogenes listed in Supplementary Table 2) in the
primary lines, MESO-3T, MESO-7T, MESO-8T, MESO-12T
and both commercial cell lines, did not reveal any genetic
alterations besides common polymorphisms (data not
shown). However, western blot analysis of p53 expression
showed that the isoform expressed by normal mesothelial
cells was also found in both commercial lines,
whereas MESO-9T, MESO-12T, MESO-14T expressed a
higher molecular weight and MESO-3T, MESO-7T,
MESO-8T, MESO-17T and MESO-27T a lower molecular
weight isoform of p53, respectively (Figure 2a). Consistent
with the reported loss of the NF2-encoded tumor suppressor
Merlin in MM clinical specimens,16,21,22 all primary cell lines
except for MESO-27T were Merlin-negative. In contrast,
Merlin was highly expressed in MSTO-211H with only low
expression observed in NCI-H2052 (Figure 2a). Examination
of the CDKN2A-encoded protein p16 detected loss of
expression in all primary cell lines except for MESO-27T, as
well as in the commercial lines. Podoplanin is a mucin-type
transmembrane glycoprotein expressed in normal cells23,24
and highly expressed in cancer25,26 with an important role in
tumor progression.24–26 Podoplanin was assessed by FACS
(Figure 3a) and confocal analysis (Figure 3b) of cells stained
with Podoplanin antibody without prior permeabilisation.
Primary cell lines showed positive staining, although
MESO-3T expressed low levels of Podoplanin on the cell
surface. In contrast, MSTO-211H cells were Podoplanin-
negative and NCI-H2052 cells displayed expression levels
similar to normal mesothelial cells (Figure 3a). Consistent
with FACS analysis, confocal microscopy showed positive
membrane staining for Podoplanin in freshly derived MM cell
lines (Figure 3b).
Status of tumor suppressor genes p16INK4A/p14ARF
and NF2. Deleterious alterations of NF2 and CDKN2A
(p16INK4A/p14ARF) have been implicated in mesothelioma
development10,16,27 and are of great importance in
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determining appropriate therapeutic strategies.16 We
examined the status of p16INK4A/p14ARF genetic loci in both
primary and commercial mesothelioma cell lines (Figure 4a
and b). Relative quantification of gene copy number
confirmed homozygous deletion of p16INK4A and p14ARF in
seven out of eight patient-derived cell lines (with the excep-
tion of MESO-27T). The commercial cell line MSTO-211H
retained the CDKN2A gene; however, the copy number was
reduced by ~ 60%, corresponding to the loss of one allele
(Figure 4a; http://cancer.sanger.ac.uk/cosmic). Despite the
presence of one p16INK4A allele, p16 protein was not
expressed in this cell line (Figure 2a) implying a mechanism
of gene silencing.28,29 Neither deletion nor silencing of p16
was found in the MESO-27T cell line as evidenced by both
gene copy number and protein expression (Figures 2a and
4a). To explore whether cell lines with p16 loss were derived
from p16-negative tumors, matching patient FFPE tumor
tissue was stained for p16 (Figure 4c). The results were
consistent with known inter-patient variability: tumor 7T was
p16-negative, whereas tumors 12T, 14T, 17T and 27T had
both p16-positive and -negative tumor cells. Patchy staining
for p16 protein may be due to deletion of p16INK4A in
some tumor cells and/or transcriptional silencing of the
p16INK4A locus.
NF2 copy number was reduced by ~50% in the primary cell
lines MESO-7T, MESO-8T, MESO-9T, MESO-12T and
MESO-14T compared with normal mesothelial cells, suggest-
ing heterozygous loss ofNF2. No change inNF2 copy number
was evident in MESO-3T, MESO-12T, MESO-17T or in either
commercial cell line (Figure 4b). Similar to p16, the pattern of
Merlin expression in patient FFPE tumor sections consisted of
both positive and negative areas (Figure 4d). However, the
majority of primary cells derived from these tumors were
Merlin-negative (Figure 2a); this included cell lines that still
retained one or both alleles of NF2, suggesting transcriptional
silencing30 or proteasomal-mediated protein degradation.31
MESO-27T was the exception, with expression of both gene
and protein (Figures 2a and 4a). However, further examination
of MESO-27T showed that Merlin was phosphorylated at
S518 (Figure 2a) and is therefore functionally inactive.32,33 In
contrast, the commercial line MSTO-211H retained both
alleles of NF2 and expressed non-phosphorylated Merlin
protein.
Primary and commercial cell lines display a different
transcriptional profile. Whole-genome transcriptional
array analysis showed a common pattern of gene
expression in all primary mesothelioma cell lines. Genes
statistically significantly up- or downregulated by more than
twofold compared with normal cells were used for further
analysis. Two-dimensional hierarchical clustering analysis
was applied to examine the relationship among the samples
in a two-dimensional plot, which clustered samples with
similarity. Similarities/differences between cell lines are
depicted by the dendrogram (Figure 5a). Strikingly, the
primary cell lines clustered together, but were distinct from
Table 1 History of asbestos exposure, histopathology results and clinical diagnosis of MM patients included in the study
Patient
sample/cell
line ID
Age Sex Asbestos exposure Histopathology Clinical diagnosis
MESO-3T 56 Male Kitchen fitter and carpenter, exposed to asbestos
through employment, asbestos fiber identified in
background lung tissue after decortication.
Epithelioid
malignant
mesothelioma
Left radical pleural decortication.
Epithelioid malignant mesothelioma,
stage at least pT2, pN0, pMx.
MESO-7T 70 Male Building contractor, exposed to asbestos through
employment, asbestos fiber identified in lung
parenchyma after decortication.
Biphasic malignant
mesothelioma
Left radical pleural decortication with
multiple station nodes. Biphasic
malignant mesothelioma, stage pT3,
pN2, pMx, R1.
MESO-8T 77 Male No known asbestos exposure and no asbestos
bodies found in lung parenchyma after
decortication.
Tumor is predomi-
nantly epithelioid
with sarcomatoid
foci
Left radical pleural decortication.
Biphasic malignant mesothelioma,
stage pT4, pN2, R1.
MESO-9T 62 Female Teacher, no asbestos exposure, no asbestos
bodies identified in lung tissue post-decortication.
Epithelioid malig-
nant mesothelioma
Left radical pleural decortication.
Epitheliod malignant mesothelioma,
stage pT4, pN2, R1.
MESO-12T 78 Male Retired engineer, no known asbestos exposure, no
asbestos bodies in specimen post-decortication.
Epithelioid malig-
nant mesothelioma
Right radical pleurectomy and
decortication. Epithelioid malignant
mesothelioma, stage pT4, pN2,
pMx, R1.
MESO-14T 59 Male Building trade, was cutting asbestos sheets when
working, strong exposure.
Epithelioid malig-
nant mesothelioma
Left pleurectomy and decortication.
Epithelioid malignant mesothelioma,
stage pT2, pN2, pMx, R1.
MESO-17T 72 Male Carpenter, has been exposed to asbestos, moder-
ate exposure.
Epithelioid malig-
nant mesothelioma
Right radical pleurectomy/ decortication.
Epithelioid malignant mesothelioma,
stage pT2 (at least), pN2, pMx, R2.
MESO-27T 65 Male Retired tin box factory worker, has been exposed to
asbestos all his working life, strong exposure.
Epithelioid malig-
nant mesothelioma
Right radical decortication of pleura.
Epithelioid malignant mesothelioma,
stage pT3, pN2, R1.
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the commercial cell lines (Figure 5a). In addition, Ingenuity
Pathway Analysis revealed that the top networks of
significantly highly represented (up- or downregulated)
pathways differed in primary and commercial cell lines
(Figure 5b). Gene Ontology (GO) term Enrichment
Analysis also showed transcriptome differences between
primary and commercial cell lines (http://chemoprofiling.org/
cgi-bin/bioprofiling/view_details.ProfCom.multi.pl?tmpdir=bio-
profiling_7168_1444663897&tool=GOdynamics&org=9606).
For example, type I interferon signaling pathway-related
genes were enriched in most of the primary but not in the
commercial cell lines (Supplementary Figure S2). Principal
Component Analysis (PCA) further revealed the relationship
between cell lines based on their gene expression pattern
(Figure 5c). On the 3D PCA plot, four separate groups
displaying a strong correlation of signals are highlighted,
which correspond to the hierarchical clustering results.
Importantly, MESO-27T, which was the only MM cell line that
retained expression of both p16 and Merlin, did not cluster
together with the other primary lines.
The transcriptome of primary MM cell lines is similar to
the transcriptional profile of other cancers. There are no
large-scale clinically annotated gene expression data sets
available for MM. Therefore, to gain new insight into the
clinical relevance of the transcriptional profile of primary MM
3T 7T 8T 9T
12T 14T 17T
7T 8T 14T 17T
3T 9T 12T 27T
27T
Figure 1 (a) Phase-contrast images of patient-derived cell lines, MESO-3T, MESO-7T, MESO-8T, MESO-9T, MESO-12T, MESO-14T, MESO-17T and MESO-27T, displaying
mesothelial morphology, scale bar indicates 100 μm. (b) Transmission electron microscopy and (c) scanning electron microscopy of primary mesothelioma cell lines showing
characteristic microvilli on the cell surface. Scale bars indicate 5 and 50 μm, respectively
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cell lines, we compared their transcriptome with 14
large-scale data sets of gene expression and clinical data for
other cancers, including breast, lung, colon, prostate, ovarian
cancer, glioma, glioblastoma and lymphomas (http://www.
chemoprofiling.org/cgi-bin/GEO/cancertarget/web_run_CT.V1.
pl). For each data set, the top genes associated with survival
were selected (e.g., top 100 genes, top 300 genes, top 500
genes, based on P-value of association). The gene groups
were then used as reference knowledge, similar to standard
GO data, to perform Enrichment Analysis. Enrichment
Analysis demonstrated that the list of genes aberrantly
expressed in MM primary cell lines was enriched by genes
significantly associated with survival in breast and lung cancer.
For example, out of the top 100 genes associated with survival
in the METABRIC data set,34 32 were present in the list of
aberrantly expressed genes in MM primary cell lines
(Supplementary Table 3), which is markedly higher than the
expected number (two genes). Consistent with this, the odds
ratio of enrichment was 15.99 (Poo0.001). The similarity of
the aberrantly expressed genes in primary MM cell lines with
the gene sets associated with survival in other cancers is
summarized in Supplementary Table 4 and Figure 5d.
Commercial cell lines are metabolically upregulated
compared with primary MM cell lines. It is well documen-
ted that tumor cells exhibit deregulated metabolism,35 which
in part explains their ability to adapt to changing conditions
within the tumor microenvironment.36 To compare the
metabolic profile of primary and commercial cell lines, cells
were analyzed using a Seahorse Flux Analyser for
assessment of both oxidative phosphorylation and glycolysis
(Figure 5e and f). Both commercial cell lines exhibited much
higher rates of glycolysis compared with primary cells
(four- to five-fold), as demonstrated by increased levels of
lactic acid release (extracellular acidification). In addition,
rates of oxygen consumption (OCR), representative of
mitochondrial oxidative phosphorylation (ox-phos), were
greatly increased (two- to four-fold) in commercial lines
compared with primary cells. These data demonstrate that
commercial mesothelioma cells lines have undergone
metabolic upregulation to depend heavily on both glycolysis
and ox-phos.37,38 Increased metabolism is depicted as a shift
highlighted by the arrow (Figure 5e), and increased basal and
ATP-linked OCR (Figure 5f). In addition, the metabolic profile
of primary cell lines was compared at low and high passage
and no difference was detected (Supplementary Figure S3).
Modified cellular metabolism clearly challenges the suitability
of these long-established MM commercial lines for studies
pertaining to metabolic flux, stage of cellular transformation
or the ability to forecast metastatic potential.39
Mesothelioma cell lines originate from tumors displaying
genomic instability. Although established primary cell lines
were authenticated by short tandem repeat (STR) DNA
profiling, their profiles were also matched to the original
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Figure 2 (a) Western blot analysis showing different expression of markers and
proteins implicated in MM pathogenesis in primary and commercial cell lines.
Immunoblotting for MM markers Calretinin and pan-Cytokeratin demonstrates inter-
patient variability; loss of Merlin expression in seven out of eight primary cell lines and high
levels of Merlin expression in commercial line MSTO-211H; phosphorylation of Merlin in
the cell line MESO-27T but not in MSTO-211H; differential expression of p53 isoforms in
patient-derived and commercial cell lines (detected by two different anti-p53 antibodies);
loss of p16 expression in seven out of eight primary cell lines and commercial cell lines.
(b) Immunofluorescence staining of commercial and primary mesothelioma cell lines for
Calretinin (green), nuclei stained with DAPI (blue). Scale bar indicates 20 μm
Figure 3 (a) Mesothelioma cell lines show differential cell surface expression of Podoplanin. Non-permeabilized normal mesothelial (Normal), commercial lines NCI-H2052
and MSTO-211H or six patient-derived lines (MESO-3T, MESO-7T, MESO-8T, MESO-9T, MESO-12T and MESO-27T) were labeled with either no primary (black), isotype control
(red), or mouse anti-Podoplanin antibody (green) and assessed by flow cytometry. Fluorescence intensity is proportional to the amount of Podoplanin on the cell surface. Normal
mesothelial cells displayed a low level of Podoplanin expression. Most lines tested showed positive staining with Podoplanin antibody, whereas MESO-3T expressed little and
MSTO-211H no Podoplanin on the cell surface. (b) Immunofluorescence staining of normal mesothelial and primary mesothelioma cell lines for transmembrane Podoplanin
(green), nuclei stained with DAPI (blue). Membrane staining is displayed by primary cell lines. Scale bar indicates 20 μm
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patient tumor genomic DNA (gDNA). The results showed
some differences between STR profiles of gDNA from a
primary cell line and the original tumor (Supplementary
Figure S4). MM is a highly heterogeneous tumor with
genomic alterations occurring in malignant cells but usually
not in the stroma. In cell lines MESO-3T, MESO-7T, MESO-
-8T, MESO-14T and MESO-27T allele numerical values for
STR loci were different from the original tumor consisting of a
mixed cell population. The MESO-7T and MESO-27T cell
lines were derived from particularly genetically unstable
tumors with four and three loci, respectively, changing the
STR size when compared with parental tumor gDNA
(Supplementary Figure S4). These differences reflect the
high degree of genomic instability of MM with changes also
evident while passaging cells in culture. Further alteration
of allele numerical values at high passages were noted
in MESO-3T, MESO-7T and MESO-14T (Supplementary
Figure S4).
Cytogenetic analysis of primary MM cell lines identified both
chromosomal structural abnormalities and changes in aneu-
ploidy status, with structural abnormalities commonly seen in
chromosomes 1, 2, 3, 6 and 7 (Table 2). Whereas similar
abnormalities were observed at early and late passages, in
some cell lines further structural abnormalities and a change
in aneuploidy status were evident at high passage (MESO-7T,
MESO-8T and MESO-27T).
Discussion
In vitro cellular models have significantly contributed to our
understanding of tumor biology and response to therapeutic
agents.6,8,9,11,12 However, successful translation of promising
pre-clinical data to the clinical setting is limited; for example,
out of a number of novel therapies recently examined in clinical
trials,40 to date none has been approved for treatment
of mesothelioma.41 The development of new therapeutic
strategies requires improved pre-clinical models that are more
physiologically relevant than long-established, widely used
commercial cell lines. Although 2D cell culture models lack the
architectural and cellular complexity of real tumors, primary
cells, nevertheless, are representative of the patient tumor
close to its native state and provide a relatively simple model
defined by the ‘robustness’ of the system for evaluating new
agents in early pre-clinical studies. Generation of primary
human mesothelioma cell lines is therefore an important tool
for studying the response of this highly chemoresistant tumor
to new therapies. Eight new mesothelioma cell lines were
established in vitro and characterized using complementary
multidisciplinary approaches. Clinically relevant markers of
mesothelioma, transcriptional and metabolic profiles, as well
as status of the tumor suppressor genes CDKN2A and NF2,
the ‘gatekeeper’ in MM development,32 were examined in the
primary cell lines and compared with those of two widely used
commercial cell lines. FACS analysis and confocal microscopy
of non-permeabilised cells immunostained for Podoplanin18,19
demonstrated that all primary cell lines displayed cell surface
expression. In contrast, the commercial cell lines tested
Podoplanin-negative or were similar to normal primary
mesothelial cells. Another important feature of the primary
cell lines was the loss of CDKN2A in seven out of eight lines.
The CDKN2A genetic locus encodes the proteins p14 and
p16; p14 activates p53 by rescuing it from proteasome-
mediated proteolysis, whereas p16 antagonizes the
cyclin-dependent kinases 4 and 6, consequently blocking cell
cycle progression.42,43 Although the TP53 gene is rarely
inactivated in MM,13,16 our observation of multiple p53
isoforms with variable expression levels in primary cell lines
emphasizes an inter-patient variability characteristic of MM. A
predominance of primary cell lines negative for p16 protein
suggests that this may have arisen from clonal selection with
p16-negative cells growingmore readily ex vivo. The presence
of p16INK4A and NF2 genes and their encoded proteins p16
andMerlin in MESO-27T indicates, however, that loss of these
proteins is not a prerequisite for successful culturing of MM
tumor cells in vitro. Alternatively, there is also the possibility
that CDKN2A/p16 was lost as cells adapted to the culture
environment. Either way, the status of key tumor suppressor
genes13–15 in cellular models should be taken into considera-
tion in experiments designed to target these pathways.44
Interestingly, although the commercial cell line MSTO-211H
displayed only heterozygous loss of the p16INK4A and p14ARF
loci, p16 protein was undetectable in these cells. This
suggests an additional mechanism, transcriptional silencing,
and exemplifies the possibility of two independent mechan-
isms simultaneously inactivating key tumor suppressor genes
in MM. The NF2 gene is mutated or homozygously deleted in
40–50% of MM,16,32,45 although established primary and
commercial cell lines show more frequent rates of mutation
or undetectable protein.46 Comparison of NF2 gene copy
number and its product Merlin, highlighted the importance of
transcriptional silencing and posttranslational modification in
MM,46; in seven out of eight primary cell lines it was observed
that, despite at least one allele being retained, Merlin was
undetectable. Furthermore, although Merlin was expressed
in cell line MESO-27T, the protein was inactivated by
phosphorylation.33
A striking difference in the transcriptional profile between
primary and commercial cell lineswas reflected by hierarchical
Figure 4 (a–d) Tumor suppressor genes and proteins in primary and commercial cell lines. (a) Relative quantification of p16INK4A/p14ARF and NF2 copy number by qPCR in
mesothelioma cell lines showing homozygous deletion of p16INK4A/p14ARF in seven out of eight patient-derived cell lines and in NCI-H2052, but not in MSTO-211H. The graphs
show relative quantification of each locus (mean of 2−ΔΔCT). (b) Relative quantification of NF2 copy number by qPCR showing heterozygous deletion of NF2 in MESO-7T,
MESO-8T, MESO-9T, MESO-14T and MESO-27T, but not in MESO-3T, MESO-12T, MESO-17T and in the commercial lines NCI-H2052 and MSTO-211H. The graph shows
relative quantification of NF2 copy number (mean of 2−ΔΔCT). (c) FFPE sections of the patient tumors stained for p16; positively stained areas are marked by arrows, the areas
marked by red arrows are shown at higher magnification. Scale bar indicate 20 μm. (d) FFPE sections of the patient tumors stained for NF2 product Merlin; positively stained
areas are marked by arrows, the areas marked by red arrows are shown at higher magnification. Scale bar indicates 20 μm
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clustering analysis, displaying that commercial cell lines
clustered together and completely separately from primary
cell lines. MESO-27T was positioned close to the other
primary cell lines, but was not included in the same cluster; this
is perhaps not surprising, considering that MESO-27T,
unlike the other primary cell lines, expresses p16 and Merlin.
Another very important difference between the primary and
commercial cell lines was unveiled by examining their
metabolic profiles. Commercial cell lines exhibited increased
metabolism compared with both low- and high-passage
primary MM cells, with a shift towards a more glycolytic
phenotype. The commercial cell lines would therefore be an
inappropriatemodel for studies exploring the cellular response
to metabolic perturbation agents, including, for example,
strategies based on synthetic lethality.47 Metabolic profiling
of cultured tumor cells is therefore essential for validation of
cell-based in vitro models.
The widely reported genomic instability of MM should also
be considered when cellular models are being developed. In
the cell line MESO-7T, TH01 (a more ‘stable’ locus48) and
three other loci had altered STR values, with a further two loci
altered at high passage, implying genomic instability of these
cells. Although we cannot fully rule out that these changes
existed before cell isolation, no peak imbalance (indicative of a
mixed cell population in the parental tumor sample) was
observed on the electropherogram (Supplementary Figure
S5), raising the possibility that these additional genetic
changes occurred while the primary cell line MESO-7T was
in culture. Consistent with this, additional chromosomal
structural abnormalities and a decrease in aneuploidy were
observed in MESO-7T at high passage. These findings
highlight that monitoring of STR profiles and aneuploidy status
is essential to determine whether further genetic alterations
are acquired during long-term culture.
GO term Enrichment Analysis revealed a similarity between
primary MM cell lines and other cancers. In particular, genes
highly associated with survival in breast and lung cancer were
enriched in the transcriptome of primary MM cell lines.
Significantly, this approach has proved to be a powerful tool
to uncover the potential clinical relevance of transcriptome
profiles in MM, and could also be of benefit in other tumor
types where no clinically annotated gene expression data sets
are available.
The key differences between primary and commercial MM
cell lines presented here highlight the importance of careful
evaluation of a pre-clinical cellular model in terms of its
suitability for a particular type of research. Although the
generation of primary cell lines is both challenging and labor
intensive, this strategy yields in vitro models that are superior
for translation of pre-clinical data to the clinical setting. Our
observation of a significantly different transcriptome profile
displayed by commercial lines and their marked metabolic
shift toward a greater glycolytic phenotype highlights the
limited suitability of long-established cell lines for translational
research. Furthermore, marked inter- and intra-patient MM
heterogeneity in terms of tumor suppressor gene status was
also evident in freshly derived cell lines, highlighting the need
for careful pre-evaluation of the suitability of MM cell-based
models used in pre-clinical testing of agents targeting p16,
p53, Merlin and related pathways.
Materials and Methods
Collection of clinical specimens. All patients underwent surgery for
radical decortication without prior chemotherapy or radiotherapy. The resected
mesothelioma specimens were collected with patient consent. Solid tumors
were immediately immersed in ice-cold RPMI-1640 supplemented with penicillin
(100 U/ml), streptomycin (100 μg/ml) and 10% FBS. Samples were transported to
the laboratory for primary cell culturing within 1 h of collection. Human investigations
were performed after Research Ethics Committee approval (LREC 08/H0406/226).
Establishment of primary cell lines. Tumor tissue was mechanically
dissociated under sterile conditions and transferred into serum-rich dissection
media (RPMI-1640 media supplemented with 10% FBS); cell release was
encouraged by mixing of the tissue suspension. Cells were collected by
centrifugation at 300 × g followed by red blood cell lysis. Cells were seeded in
gelatin-coated flasks at 5 × 104/cm2 and maintained in RPMI-1640 growth
media supplemented with L-glutamine (2 mM), penicillin (100 U/ml), streptomycin
(100 μg/ml), hEGF (20 ng/ml), hydrocortisone (1 μg/ml), heparin (2 μg/ml) and 2%
FBS at 37 °C and 5% CO2. Differential trypsinisation with 0.05 and 0.1% trypsin
was used to remove fibroblasts and select mesothelial cells, respectively. Culture
purity varied from 97% (owing to occasional non-proliferating fibroblasts) to 100% of
malignant mesothelial cells. After the cell lines were established they were cultured
in RPMI-1640 growth media supplemented with L-glutamine (2 mM), penicillin
(100 U/ml), streptomycin (100 μg/ml), hEGF (20 ng/ml), hydrocortisone (1 μg/ml),
heparin (2 μg/ml) and 10% FBS at 37 °C and 5% CO2. Cells were monitored
regularly for their morphology. All cell lines were authenticated by STR DNA profiling
(LGC Standards, Teddington, UK) and matched to the original tumor tissue. All cell
culture reagents were from Life Technologies (Paisley, UK), except for
hydrocortisone and heparin (Sigma-Aldrich, Dorset, UK).
Figure 5 (a) Gene expression pattern and hierarchical clustering of control (NM - cells from a single donor and NMS - pool from four donors), commercial (MSTO-211H, NCI-
H2052) and primary mesothelioma cell lines (3T, 7T, 8T, 9T, 12T, 14T, 17T, 27T). RNA was extracted from at least three independent cultures for each cell line. The heat-map
displays the expression level of the most variable transcripts across the samples (fold change42 compared with NM control). The legend bar shows the color code for the
normalized log intensity values. Two-dimensional hierarchical clustering was performed using the average linkage-clustering method. Relationships among the cell lines are
represented by a binary tree (dendrogram). The vertical position of the split gives the distance (dissimilarity) between the tested cell lines. (b) Top networks in the transcriptome.
Significantly highly represented networks were identified. Networks that were significantly highly represented (P≤ 10− 10; Fischer’s exact test) were identified from the gene list,
with significant difference (ANOVA) compared with normal mesothelial cells, using Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, CA, USA). The
network score describes the probability (P= 10-network score) that the molecules in the network are associated with the data set by chance alone. Networks with a score of +30 were
viewed as highly significant (10=minimum score). (c) 3D plot of the scores from Principal Component Analysis. Four separate groups corresponding to the hierarchical clustering
results were highlighted by circles (i-commercial cell lines, ii- seven primary cell lines, iii- MESO-27T cell line and iv-normal primary mesothelial cells) and present a strong
correlation of signals (d), Enrichment profile across 15 data sets (the best hit for each data set is plotted) showing high similarity (***) of MM primary cell lines to lung and breast
cancer (odds ratio410) and similarity (**) to glioma and prostate cancer (odds ratio45) in terms of aberrantly expressed genes. (e) Metabolic upregulation of commercial
compared with primary cell lines. To assess the difference in metabolism between primary and commercial mesothelioma lines, 5 × 104 cells were seeded in XF24 microplates
24 h prior to real time measurements of oxidative phosphorylation (OCR) and extracellular acidification rate (ECAR) as described in Materials and Methods. Basal values of OCR
and ECAR were calculated from mean values generated from three independent experiments normalized to 5 × 104 cells. Data points show mean±S.E.M., n= 3. Increased
metabolism is depicted as a shift highlighted by the arrow. (f) Basal and ATP-linked OCR mean values were calculated from three independent experiments normalized to 5 × 104
cells. Bars show mean± S.E.M., n= 3
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Commercial cell lines. Two mesothelioma cell lines, MSTO-211H and
NCI-H2052, were obtained from the American Type Culture Collection (Manassas,
VA, USA) and cultured in RPMI-1640 supplemented with L-glutamine (2 mM),
penicillin (100 U/ml), streptomycin (100 μg/ml) and 10% FBS in a 5% CO2
humidified incubator at 37 °C. Adult human primary omental mesothelial cells
(single or multi-donor) purchased from Cambridge Bioscience (Cambridge, UK)
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served as normal controls (Normal) and were maintained in culture in growth
medium (Medium 199, 10% FBS, 20 ng/ml hEGF, 100 U/ml penicillin, 100 μg/ml
streptomycin) for up to three passages.
Electron microscopy. For transmission electron microscopy (TEM), cell
pellets were fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4)
at 4 °C overnight and postfixed with 1% osmium tetroxide/1% potassium
ferrocyanide for 1 h at room temperature. After fixation, cells were stained en
bloc with 5% aqueous uranyl acetate overnight at room temperature, dehydrated
in a series of alcohols and embedded in Taab epoxy resin (Taab Laboratories
Equipment Ltd., Aldermaston, UK). Confluent cultures, in plastic dishes, were also
processed in situ before the plastic was removed, with propylene oxide, and the
blocks re-embedded for orthogonal sectioning. Ultra-thin sections were stained with
lead citrate and recorded using a Megaview 3 digital camera and iTEM software
(Olympus Soft Imaging Solutions GmbH, Münster, Germany) in a Jeol 100-CXII
electron microscope (Jeol UK Ltd., Welwyn Garden City, UK).
For scanning electron microscopy, cells on glass coverslips were processed
to absolute alcohol, as for TEM, transferred to hexamethyldisilazane and
air-dried before being sputter-coated with a 15 nm layer of gold and examined
in a FEI Quanta FEG 250 electron microscope (FEI Europe, Eindhoven, the
Netherlands).
Flow cytometry analysis. MM cell suspension (1 × 106/ml) was incubated at
4 °C for 1 h with anti-Podoplanin antibody (1 : 100, Santa Cruz, Middlesex, UK;
sc-59347) or isotype control antibody (Mouse anti-BCL-2). Cells were pelleted,
washed and re-suspended in normal medium containing goat anti-mouse IgG
conjugated with FITC (1 : 100, Dako, Cambridge, UK) and incubated for 1 h at 4 °C.
Cells were washed and re-suspended in PBS before analysis by BD FACS Calibur;
data were acquired and analyzed with CellQuest software.
Western blot analysis. Cells were lysed for 20 min on ice in lysis buffer
(50 mM Tris pH 7.5, 0.5 M NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS,
2 mM EDTA, and complete protease inhibitors (Roche, Basel, Switzerland)), briefly
sonicated and the resultant lysate clarified by centrifugation at 1000 × g for 10 min.
Protein content was measured by Bradford assay and 20 μg protein was loaded
onto 4–20%, Criterion TGX gels (Bio-Rad Laboratories, Hemel Hempstead, UK).
Proteins were blotted onto polyvinylidene difluoride membranes (Millipore, Watford,
UK). Immunoblotting was done after blocking with 5% non-fat milk with the following
primary antibodies: anti-Merlin mAb D1D8 and anti-p53 (7F5) (Cell Signaling,
Hitchin, UK), anti-p53 (DO-1), and anti-pan-Cytokeratin (H-240) (Santa Cruz),
anti-Vinculin mouse, anti-Merlin (phospho-S518) rabbit (Abcam, Cambridge, UK),
anti-p16 (G175–405) and anti-Calretinin mouse (BD Bioscience, Oxford, UK). Bands
were detected using fluorescently-labeled secondary antibodies (LiCor Biosciences,
NE, USA) according to the manufacturer's recommendations. The membranes were
subsequently scanned with an Odyssey Infrared Imager (LiCor Biosciences) and
converted to greyscale.
Immunohistochemistry and immunofluorescence. Immunohisto-
chemistry of formalin-fixed, paraffin-embedded tissues from human explants
was performed with the Histostain-Plus detection System according to the
manufacturer's protocol (Life Technologies). Sections were dewaxed and
rehydrated, and antigen retrieval was performed by heating the slides in 10 mM
citric acid buffer (pH 6.0) for 15 min. Sections were incubated overnight at 4 °C in a
humidified chamber with a 1 : 10 dilution of antibody to p16 (BD) and 1 : 50 NF2
(Santa Cruz). Control IHC experiments (data not shown) were performed without
primary antibody. All sections were counterstained with Gill's haematoxylin and
mounted for digital slide scanning.
For immunofluorescence, isolated cells were first fixed in 4% paraformaldehyde
and where indicated permeabilized with 0.1% Triton in PBS-Tween (0.1% vol/vol),
prior to blocking in 5% goat serum in PBS-Tween. Cells were then incubated with
primary antibody 1 : 50 anti-Podoplanin (Santa Cruz) without prior permeabilization;
1 : 50 anti-Calretinin (Cell Signaling) overnight at 4 °C. Cells were washed three times
for 10 min each with 1 × PBS, incubated for 1 h with secondary antibody (in blocking
solution), washed three times with 1 × PBS, and counterstained with DAPI and
mounted for confocal microscopy.
RNA microarrays. Total RNA was extracted by TRIzol (Life Technologies).
Hybridization to 60 K whole human genome microarray gene expression chips was
conducted following manufacturer’s protocol (Agilent Technologies, Berkshire, UK).
In brief, total RNA samples were Cy3-labeled using Agilent Low Input Quick
Table 2 Cytogenetic analysis of primary MM cell lines
Cell line Passage Chromosome
count
Structural abnormalities of
chromosomes
Overview
MESO-3T Low ~66–4200 Structural abnormalities present. Range of ploidy levels seen at both low and high passage
High ~59–4200 Structural abnormalities present. but no overall change between low and high. Structural
abnormalities are present (particularly chromosome 1).
MESO-7T Low 69–78 1, 3, 6, 7, 8, 9, 10, 11, 13, 17 Decrease in aneuploidy between low and high passage.
High 43 1, 2, 4, 5, 11, 15 Different structural abnormalities seen at high passage only.
MESO-8T Low 63–67 1, 3, 6, 7, 8, 9, 13, 21 Increase in aneuploidy between low and high passage;
High 73–79 1, 3, 6, 7, 8, 9, 10, 13. Doubling of
some structural abnormalities.
doubling of some structural abnormalities seen at low passage.
Some abnormalities seen only at low passage and vice-versa.
MESO-12T Low 46 1, 2, 6, 9, 11, 12, 14, 17, 20, 22 No change in aneuploidy. Some minor changes to structural
High 46 1, 2, 6, 7, 8, 9, 11, 12, 14,
16, 17, 22
rearrangement between low and high passage.
MESO-14T Low 47–48 1, 2, 6, 7, 8, 9, 11, 12, 16, 17 No significant change in aneuploidy. Some minor changes to
High 46–47 1, 2, 6, 7, 8, 9, 11, 12, 17 structural rearrangement between low and high passage.
MESO-27T Low 72–74 Y, 1, 2, 3, 7, 9, 11, 12, 13, 14, 16,
17, 19, 20
General decrease in aneuploidy at high passage. Some minor
changes to structural rearrangement between low and high
High 65–73 Y, 1, 3, 7, 8, 13, 14, 16, 17, 19, 22 passage.
MESO-9T Low ~46 Structural abnormalities present. Evidence of doubling of chromosome number; may be due to
cultural tetraploidy.
MESO-17T Low 44–46 8, 19. Missing a Y-chromosome
and one chromosome 6.
Less complexity with only a single structural abnormality in each
cell along with the loss of whole chromosomes. Evidence of a
doubling of chromosome number; may be due to cultural
tetraploidy.
Where indicated, actively growing MM cells were analyzed at low and high passage.
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Amp 1-colour Labelling Kit. The level of dye incorporation was evaluated by
spectrophotometry (Nanodrop ND1000, LabTech, Uckfield, UK). Labeled RNA was
then fragmented and diluted (v/v) in hybridization buffer. Hybridization to 60 K
high-density oligonucleotide microarray slides was performed in a microarray
hybridization oven overnight at 65 °C. Following hybridization, the slides were rinsed
and immediately scanned using a DNA Microarray Scanner (Model G2505C, Agilent
Technologies).
Analysis of microarray data. The raw data were uploaded into Agilent's
GeneSpring Software, normalized and fold changes calculated. For each cell line
the probes with an absolute twofold-change (Po0.05) in mRNA expression
compared to normal mesothelial cells were included in subsequent analyses. These
were subjected to Anova unequal variations test with Benjamin–Hochberg
corrections. Significant (Po0.05) changes were subjected to hierarchical clustering
with average linkage. The clustered heat-map was visualized using GeneSpring.
Significantly highly represented networks were identified using Ingenuity Pathway
Analysis software (Ingenuity Systems, Redwood City, CA, USA). The PCA
(statistical procedure elucidating the covariance structure of a set of variables) was
performed for the three most changing components to identify the principal
directions in which the mRNA changes varied. The data were projected on three
axes (components), ordered by decreasing significativity; the first principal
component explains 20.2% of the variance, the second explains 14.99% and the
third explains 14.45% of the variations in expression. GO term Enrichment Analysis
was conducted as described previously.49,50
Relative quantification of gene copy number by real-time
PCR. gDNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen,
Manchester, UK) according to the manufacturer’s instructions. An assay based
on the paralogue ratio test and real-time PCR was used to determine the DNA copy
number as described previously.51
Real-time PCRs were performed on the ABI 7500 Fast system (Applied
Biosystems Foster City, CA, USA). Each 10-μl reaction contained 3.4 μl of gDNA
(10 ng), 0.3 μl of each of the two primers required for each loci (20 pM), 0.2 μl of each
of the probes required (50–200 nM), and 5 μl of Genotyping MasterMix (Applied
Biosystems). The PCRs began with 2 min at 50 °C, 10 min at 95 °C, followed by a
cycle consisting of 15 s at 95 °C and 60 s at 60 °C. Fifty cycles were performed. CT
values were determined using the automatic threshold settings. gDNAs from diploid
control (Roche, human gDNAs, catalog #11691112001) and normal mesothelial cells
were used as controls. The ΔCT was calculated for each of the reactions using
the following equation: CT gene 1 (gene of common DNA loss)−CT gene 2
(reference)=ΔCT. The mean ΔCT from at least three reactions was used for
subsequent analysis. The relative quantification of copy number was calculated using
the 2−ΔΔCT value. Primers and probes are listed below:
Target locus Location Primer probe Sequence
p16 Chromosome 9:
21967752..21994491,
complement
Forward primer
Reverse primer
Probe
5′-AACATGGTGCGCAGGTTCTT-3′
5′-TGAACCACGAAAACCCTCACT-3′
5′-6-FAM-CCCTCCGGATTCG-MGB-3′
p14 Chromosome 9:
21967752..21994491,
complement
Forward primer
Reverse primer
Probe
5′-GCGGTCCCTCCAGAGGAT-3′
5′-CGGTGCTGGCGGAAGA-3′
5′-6-FAM-TGAGGGACAGGGTCG-MGB-3′
NF2 Chromosome 22:
29999545..30094589
Forward primer
Reverse primer
Probe
5′- GCCAGGCCCTGCTAGATAGC-3′
5′-AACCTGTCCCCAAAATTACAAGAC-3′
5′-6-FAM- CCCCGTGGCATTAC-MGB-3′
AldoB (aldolase B,
reference)
Chromosome 9:
101420560..101435780,
complement
Forward primer
Reverse primer
Probe
5′-TTTCCACGAGACCCTCTACCA-3′
5′-CTTTTCCTTGAGGATGTTTCTGAAC-3′
5′-6-FAM- AAGGACAGCCAGGGAA-MGB-3′
Svil (supervillin,
reference)
Chromosome 10:
29457338..29736935
Forward primer
Reverse primer
Probe
5′-GCCTGCGGAGCGTCAA-3′
5′-GGCACGGCGCTGTTGT-3′
5′-6-FAM-ACGGAACAGAACTCT-MGB-3′
Cell metabolism assays. Rates of oxidative phosphorylation and glycolysis
were determined by measuring the rate of OCR and extracellular acidification rate
(ECAR), respectively, using a Seahorse XF24 extracellular flux (XF) analyser
(Seahorse Bioscience, Billerica, MA, USA).
Commercially available and primary MM cell lines were seeded in a XF24 cell
culture microplate at 5 × 104 cells/well 24 h before the assay and incubated at 37 °C
under 5% CO2 in a humidified atmosphere. Primary lines were seeded on gelatin
coated microplates. 24 h prior to assay, 1 ml of Seahorse calibrant was added to each
well of a Seahorse XF24 utility plate and the probes on the sensor cartridge were
allowed to soak at 37 °C under CO2-free conditions. 1 h prior to assay, cells were
washed 3 × in unbuffered bicarbonate and serum-free DMEM (pH 7.4) containing
1 mM sodium pyruvate, 11 mM glucose and 2 mM glutamax; then covered in 675 μl
of the same media, and incubated for 1 h at 37 °C under CO2-free conditions. The cell
microplate was then loaded into the Seahorse XF24 and assayed to measure basal
OCR and ECAR.
Cytogenetic analysis. Chromosome preparations of the cells were made as
follows: Colcemid (Gibco Invitrogen, Paisley, UK; 10 μg/ml in PBS) (0.3 μg/ml final
concentration) was added to semi-confluent actively dividing cultures 4 h before
harvesting. Metaphase cells were harvested by trypsinizing, treated with a hypotonic
solution (deionised water) for 15 min at 37 °C and fixed twice in acetic acid (one
part)/methanol (three parts). Cells were dropped onto clean slides, heat-aged,
treated with trypsin and stained with Leishman stain to produce G-banded
chromosomes. In total, 4–10 metaphase spreads were analyzed from each culture,
depending on availability, for numerical and structural rearrangements.
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